Replay
The Sound Kitchen
The walking library
 
Listen Download Podcast
  • RFI English News flash 04h00 - 04h10 GMT Mon-Fri
    News bulletin 01/21 04h00 GMT
  • Paris Live AM 04h10 - 04h30 GMT Mon-Fri
    Features and analysis 01/21 04h10 GMT
  • RFI English News flash 05h00 - 05h10 GMT Mon-Fri
    News bulletin 01/21 05h00 GMT
  • Paris Live AM 05h10 - 05h30 GMT Mon-Fri
    Features and analysis 01/21 05h10 GMT
  • RFI English News flash 06h00 - 06h10 GMT Mon-Fri
    News bulletin 01/21 06h00 GMT
  • Paris Live AM 06h10 - 06h30 GMT Mon-Fri
    Features and analysis 01/21 06h10 GMT
  • RFI English News flash 06h30 - 06h33 GMT Mon-Fri
    News bulletin 01/21 06h30 GMT
  • Paris Live AM 06h33 - 06h59 GMT Mon-Fri
    Features and analysis 01/21 06h33 GMT
  • RFI English News flash 07h00 - 07h10 GMT Mon-Fri
    News bulletin 01/21 07h00 GMT
  • RFI English News flash 07h30 - 07h33 GMT Mon-Fri
    News bulletin 01/21 07h30 GMT
  • RFI English News flash 14h00 - 14h03 GMT Sat-Sun
    News bulletin 01/21 14h00 GMT
  • RFI English News flash 14h00 - 14h06 GMT Mon-Fri
    News bulletin 01/19 14h00 GMT
  • Paris Live Weekend 14h03 - 14h30 GMT Sat-Sun
    Features and analysis 01/21 14h03 GMT
  • Paris Live PM 14h06 - 14h30 GMT Mon-Fri
    Features and analysis 01/19 14h06 GMT
  • RFI English News flash 14h30 - 14h33 GMT Mon-Fri
    News bulletin 01/21 14h30 GMT
  • Paris Live PM 14h33 - 14h59 GMT Mon-Fri
    Features and analysis 01/21 14h33 GMT
  • RFI English News flash 16h00 - 16h03 GMT Sat-Sun
    News bulletin 01/21 16h00 GMT
  • RFI English News flash 16h00 - 16h06 GMT Sat-Sun
    News bulletin 01/19 16h00 GMT
  • Paris Live Weekend 16h03 - 16h30 GMT Sat-Sun
    Features and analysis 01/21 16h03 GMT
  • RFI English News flash 16h30 - 16h33 GMT Mon-Fri
    News bulletin 01/21 16h30 GMT
  • Paris Live Weekend 16h33 - 17h00 GMT Sat-Sun
    Features and analysis 01/21 16h33 GMT
To take full advantage of multimedia content, you must have the Flash plugin installed in your browser. To connect, you need to enable cookies in your browser settings. For an optimal navigation, the RFI site is compatible with the following browsers: Internet Explorer 8 and above, Firefox 10 and +, Safari 3+, Chrome 17 and + etc.
Afp

Treatment against blindness to sell for $850,000 in US

By AFP
media A new drug, Luxturna, is entering a growing field of super-expensive medications AFP/File

Luxturna, a medication against hereditary degeneration of the retina that can lead to total blindness, will be sold for $850,000 in the United States, making it one of the world's most expensive medical treatments.

It is administered in a single dose, according to its manufacturer, Philadelphia-based Spark Therapeutics.

It will retail for $425,000 per eye, which is less than the $1 million price tag that had been expected before the company received FDA approval in mid-December.

The announcement comes amid a growing debate in the United States over the high cost of medicine, particularly for supposedly innovative treatments.

Anticipating criticism, Spark promised to reimburse patients if the treatment proves not to be effective, and said it expects US health authorities to authorize payment in stages.

In doing so, the company is following the lead of Novartis, which sells Kymriah, a treatment for a very aggressive form of leukemia in children and young adults. The Swiss drug maker has pledged to reimburse insurers and patients if the $475,000 drug doesn't work.

Luxturna is considered the first American medication to emerge from gene therapy, which consists of repairing a defective gene.

There are currently about 1,000 cases of people who suffer from hereditary degeneration of the retina, and 10 to 20 new cases are expected to be added each year.

Besides Luxturna, several other medications are near the million-dollar price mark, although they are often administered in several doses.

Such is the case with Spinraza (known as Nusinersen in Europe), developed by Biogen and Ionis against muscular dystrophy, and Soliris, made by Alexion Pharmaceuticals to treat a rare form of kidney disease. Both cost around $750,000.

The prize for the world's most expensive medication goes to Glybera, which its Dutch developer UniQure sells for $1 million as a treatment for several genetic maladies.

 
Sorry but the period of time connection to the operation is exceeded.